Merit Medical Systems, Inc. Files 8-K: Detailed Product Revenue Disclosures for Investors

Date of Report: April 13, 2026
Exchange: NASDAQ Global Select Market
Ticker: MMSI
Registrant: Merit Medical Systems, Inc.
Headquarters: 1600 West Merit Park Way, South Jordan, UT 84095

Key Highlights from the 8-K Filing

• Purpose of the Filing: The company furnished supplemental historical revenue information, reclassifying sales by new product categories and platforms for the years ended December 31, 2025, 2024, 2023, and 2022, as well as by quarter for 2024 and 2025.
• Regulation FD Disclosure: The information is furnished under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
• No Indication of Emerging Growth Status: The company is not an emerging growth company and has not elected to use any extended transition period for complying with new accounting standards.
• No Pre-commencement or Soliciting Material: The company confirms that the filing does not pertain to written communications, soliciting materials, or pre-commencement tender offers.
• Product Revenue Breakdown: Extensive, detailed breakdowns of product sales by category/platform and quarter, offering transparency on business segment performance.

Detailed Revenue Disclosures by Product Category

Merit Medical Systems has provided shareholders with a highly detailed look into its revenue streams, reporting on the performance of its various product categories over multiple years and quarters. This level of granularity is not typically available in standard quarterly or annual filings, and it can offer valuable insights for investors evaluating the company’s direction and execution.

Annual Revenue by Product Category (2022 – 2025)

Quarterly Revenue by Product Platform (2024 & 2025)

The company also disclosed unaudited quarterly revenue figures by product platform for 2024 and 2025, offering investors a clear picture of seasonal trends and platform momentum.

Shareholder-Relevant and Potentially Price-Sensitive Information

• Transparency in Revenue Reporting: Management’s decision to disclose this granular, supplemental revenue data by product platform and quarter may indicate a strategic shift toward greater transparency, possibly in response to investor demand for clarity on business segment performance. This can be seen as a positive for shareholders seeking to model the business more accurately.
• No Announced M&A, Guidance, or Restructuring: The filing does not reference any merger or acquisition activity, changes to guidance, or restructuring events, meaning the primary “news” is the enhanced reporting detail.
• No Indication of Material Change: The filing explicitly states the information is “furnished” under Regulation FD and not “filed,” meaning it is not considered part of the official financial statements, and no restatement or revision is implied.

Why This Disclosure May Move the Share Price

Enhanced investor confidence: By providing a clear breakdown of revenue by product lines and over multiple periods, Merit Medical is enabling shareholders and analysts to better understand growth drivers, cyclical trends, and platform-level performance. This could reduce uncertainty and improve investor confidence in management’s transparency.

Benchmarking and Modeling: Investors may use this data to update their financial models, potentially leading to revisions in consensus estimates if the underlying trends in product platforms differ from what was previously assumed.

Sector Comparison: Such detailed disclosures could be used to benchmark Merit Medical’s segment performance against peers, providing a competitive context that may influence market perception of the company’s growth prospects.

Conclusion

While the 8-K does not contain news of an M&A event, new product launch, major contract, or guidance change (all of which typically have outsized price impacts), the enhanced transparency and granularity in revenue reporting is notable. For long-term investors and analysts, this kind of disclosure is valuable for understanding the company’s revenue drivers and could lead to a positive market response as uncertainty is reduced.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors should perform their own due diligence and consult with a qualified financial advisor before making investment decisions. The information is based on the company’s 8-K filing as of April 13, 2026, and the company may release additional information or updates in the future.

View MERIT MEDICAL SYSTEMS INC Historical chart here